CBD administration reduces blood pressure levels, according to a meta-analysis of randomized placebo-controlled trials published in the Brazilian Journal of Pharmacognosy.
Brazilian researchers reviewed data from four clinical trials involving 104 participants. Study results “demonstrated a significant reduction in systolic blood pressure after acute cannabidiol.” CBD dosing also resulted in reductions in diastolic blood pressure, although these changes were not statistically significant.
“These findings suggest that cannabidiol may benefit blood pressure control, specifically with prolonged use in hypertensive patients,” the study’s authors concluded. “But further high-quality randomized controlled trials are required to approve its efficacy, safety, and clinical applicability in cardiovascular care.”
Longitudinal data published earlier this month concluded that the cumulative lifetime cannabis use is not associated with an elevated risk of high blood pressure.
A prior analysis of over 91,000 French adults, published in the journal Nature: Scientific Reports, reported that both current and lifetime cannabis use is associated with lower blood pressure. Another study, published in the European Journal of Internal Medicine, noted that the use of medical cannabis products is associated with decreases in hypertension among elderly subjects.
Full text of the study, “Systematic review and meta-analysis to investigate the effects of cannabidiol on blood pressure: Examination of randomized double-blind and triple-blind placebo trials,” appears in the Brazilian Journal of Pharmacognosy. Additional information on cannabinoids and blood pressure regulation is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.
